Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

KELLEY WILSON

Allopathic & Osteopathic Physicians Psychiatry & Neurology Psychiatry

NPI
1932398757
CMS profile
224261
Location
TAMPA, FL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2019 · Entire year

$3,773.33

11 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2019 · entire year · sorted by reported total

By paying entity

PY2019 · entire year · sorted by reported total

Paying entityAmountRecords
Janssen Pharmaceuticals, Inc $2,724.99 3
Neuronetics, Inc. $1,048.34 8

Page 1 of 1; records 1–11 of 11 matching records. This page contains 11 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

KELLEY WILSON

NPI 1932398757 · CMS profile ID 224261

Allopathic & Osteopathic Physicians / Psychiatry & Neurology / Psychiatry

TAMPA, FL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–11 of 11 matching records. This page contains 11 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1932398757?year=2019&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
KELLEY WILSON, NPI 1932398757, CMS profile ID 224261. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–11 of 11 matching records. This page contains 11 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1932398757?year=2019&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
APA 7
IndustryPayments. (2026). KELLEY WILSON, NPI 1932398757, CMS profile ID 224261. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–11 of 11 matching records. This page contains 11 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1932398757?year=2019&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
Bluebook
KELLEY WILSON, NPI 1932398757, CMS profile ID 224261, IndustryPayments, General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–11 of 11 matching records. This page contains 11 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e. https://industrypayments.org/provider/npi-1932398757?year=2019&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2019

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2019 · Physicians and non-physician practitioners · CMS publication 2026-06-30

11 matching records · $3,773.33 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 11 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–11 of 11.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Neuronetics, Inc. $3.7308/16/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 686649897 CMS
Neuronetics, Inc. $537.7007/27/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 663187319 CMS
Neuronetics, Inc. $50.8807/27/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 663187325 CMS
Neuronetics, Inc. $73.7207/27/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 663187330 CMS
Neuronetics, Inc. $93.0507/27/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 663187335 CMS
Neuronetics, Inc. $84.3207/27/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 686649895 CMS
Neuronetics, Inc. $159.2207/26/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 686649893 CMS
Janssen Pharmaceuticals, Inc $1,600.0006/21/2019 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 659392323 CMS
Janssen Pharmaceuticals, Inc $124.9906/18/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 659392321 CMS
Janssen Pharmaceuticals, Inc $1,000.0005/29/2019 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 659392319 CMS
Neuronetics, Inc. $45.7203/14/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 686649891 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $3,773.33 11
PY2020 $65.09 3
PY2021 $268.69 10
PY2022 $389.28 8
PY2023 $1,820.04 73
PY2024 $683.61 29
PY2025 $717.46 3

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $2,698,890.20 111
PY2024 Principal investigator $3,248,583.50 103
PY2023 Recipient $1,039.86 1
PY2023 Principal investigator $1,084,081.62 189
PY2022 Recipient $1,428.00 1
PY2022 Principal investigator $532,395.28 190
PY2021 Recipient $1,678.03 1
PY2021 Principal investigator $1,711,588.07 233
PY2020 Principal investigator $1,081,919.61 115
PY2019 Principal investigator $698,002.09 160

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2019

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

160 records in PY2019

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Allergan Inc. $600.00 12/31/2019 Non-covered Recipient Entity
ACADEMIC ALLIANCE IN DERMATOLOGY OLYMPIAN CLINICA
A DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF CARIPRAZINE AS ADJUNCTIVE THERAPY IN MAJOR DEPRESSIVE DISORDER No dispute reported 06/30/2026 670123423
Principal investigator 1 Janssen Research & Development, LLC $2,500.00 12/30/2019 Non-covered Recipient Entity
ACADEMIC ALLIANCE IN DERMATOLOGY
A Prospective, Matched-Control, Randomized, Open-Label, Flexible-Dose, Study in Subjects With Recent-Onset Schizophrenia or Schizophreniform Disorder to Compare Disease Progression and Disease Modification Following Treatment With Paliperidone Palmitate Long-Acting Injection or Oral Antipsychotics No dispute reported 06/30/2026 654241445
Principal investigator 1 Janssen Research & Development, LLC $1,020.00 12/30/2019 Non-covered Recipient Entity
ACADEMIC ALLIANCE IN DERMATOLOGY
A Phase 2, Multicenter, Randomized, Placebo-Controlled, Double-Blind, Proof-of-Concept Study to Evaluate Guselkumab for the Treatment of Subjects with Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 654241481
Principal investigator 1 AbbVie, Inc. $225.00 12/26/2019 Non-covered Recipient Entity
ACADEMIC ALLIANCE IN DERMATOLOGY, INC.
M16-045 No dispute reported 06/30/2026 647590361
Principal investigator 1 Janssen Research & Development, LLC $6,452.00 12/23/2019 Non-covered Recipient Entity
ACADEMIC ALLIANCE IN DERMATOLOGY
A Phase 2, Multicenter, Randomized, Placebo-Controlled, Double-Blind, Proof-of-Concept Study to Evaluate Guselkumab for the Treatment of Subjects with Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 654241479
Principal investigator 1 AbbVie, Inc. $8,397.47 12/12/2019 Non-covered Recipient Entity
ACADEMIC ALLIANCE IN DERMATOLOGY, INC.
M16-045 No dispute reported 06/30/2026 647590363
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $500.00 12/05/2019 Non-covered Recipient Entity
ACADEMIC ALLICANCE IN DERMATOLOGY INC
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Risperidone Extended-Release Injectable Suspension (TV-46000) for Subcutaneous Use as Maintenance Treatment in Adult and Adolescent Patients With Schizophrenia No dispute reported 06/30/2026 685012281
Principal investigator 1 Janssen Research & Development, LLC $1,500.00 11/29/2019 Non-covered Recipient Entity
ACADEMIC ALLIANCE IN DERMATOLOGY
A Prospective, Matched-Control, Randomized, Open-Label, Flexible-Dose, Study in Subjects With Recent-Onset Schizophrenia or Schizophreniform Disorder to Compare Disease Progression and Disease Modification Following Treatment With Paliperidone Palmitate Long-Acting Injection or Oral Antipsychotics No dispute reported 06/30/2026 654241441
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $42.00 11/28/2019 Non-covered Recipient Entity
ACADEMIC ALLICANCE IN DERMATOLOGY INC
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Risperidone Extended-Release Injectable Suspension (TV-46000) for Subcutaneous Use as Maintenance Treatment in Adult and Adolescent Patients With Schizophrenia No dispute reported 06/30/2026 685012277
Principal investigator 1 Avanir Pharmaceuticals, Inc. $4,258.70 11/21/2019 Non-covered Recipient Entity
OLYMPIAN CLINICAL RESEARCH
15-AVP-786-303 No dispute reported 06/30/2026 656018073
Principal investigator 1 Avanir Pharmaceuticals, Inc. $14.89 11/14/2019 Non-covered Recipient Entity
OLYMPIAN CLINICAL RESEARCH
15-AVP-786-303 No dispute reported 06/30/2026 656018071
Principal investigator 1 AbbVie, Inc. $4,143.80 11/13/2019 Non-covered Recipient Entity
ACADEMIC ALLIANCE IN DERMATOLOGY, INC.
M16-045 No dispute reported 06/30/2026 647590365
Principal investigator 1 Janssen Research & Development, LLC $3,280.00 11/08/2019 Non-covered Recipient Entity
ACADEMIC ALLIANCE IN DERMATOLOGY
A Phase 2a Randomized, Double-blind, Placebo-Controlled, Parallel-Group, Multi-center Study Investigating the Efficacy, Safety, Tolerability and Pharmacokinetics of JNJ67953964 in Subjects with Major Depressive Disorder. No dispute reported 06/30/2026 654241485
Principal investigator 1 Janssen Research & Development, LLC $3,698.00 11/04/2019 Non-covered Recipient Entity
ACADEMIC ALLIANCE IN DERMATOLOGY
A Phase 2, Multicenter, Randomized, Placebo-Controlled, Double-Blind, Proof-of-Concept Study to Evaluate Guselkumab for the Treatment of Subjects with Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 654241483
Principal investigator 1 Eisai Inc. $7.50 10/29/2019 Non-covered Recipient Entity
ACADEMIC ALLIANCE IN DERMATOLOGY
A Placebo-Controlled, Double-Blind, Parallel-Group, 24 Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702536245
Principal investigator 1 Eisai Inc. $75.00 10/29/2019 Non-covered Recipient Entity
ACADEMIC ALLIANCE IN DERMATOLOGY
A Placebo-Controlled, Double-Blind, Parallel-Group, 24 Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702536247
Principal investigator 1 Eisai Inc. $1,032.00 10/29/2019 Non-covered Recipient Entity
ACADEMIC ALLIANCE IN DERMATOLOGY
A Placebo-Controlled, Double-Blind, Parallel-Group, 24 Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702536249
Principal investigator 1 Eisai Inc. $175.00 10/29/2019 Non-covered Recipient Entity
ACADEMIC ALLIANCE IN DERMATOLOGY
A Placebo-Controlled, Double-Blind, Parallel-Group, 24 Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702536251
Principal investigator 1 Allergan Inc. $225.00 10/22/2019 Non-covered Recipient Entity
COPERNICUS GROUP INCORPORATED DBA COPERNICUS GROUP
AN OPEN LABEL, LONG TERM SAFETY STUDY OF RAPASTINEL AS AN ADJUNCTIVE THERAPY IN PATIENTS WITH MAJOR DEPRESSIVE DISORDER MDD. No dispute reported 06/30/2026 670088235
Principal investigator 1 Janssen Research & Development, LLC $3,473.00 10/18/2019 Non-covered Recipient Entity
ACADEMIC ALLIANCE IN DERMATOLOGY
A Phase 2, Multicenter, Randomized, Placebo-Controlled, Double-Blind, Proof-of-Concept Study to Evaluate Guselkumab for the Treatment of Subjects with Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 654241477
Principal investigator 1 AbbVie, Inc. $5,779.75 10/11/2019 Non-covered Recipient Entity
ACADEMIC ALLIANCE IN DERMATOLOGY, INC.
M16-045 No dispute reported 06/30/2026 647590359
Principal investigator 1 Boehringer Ingelheim International GmbH $35.00 10/01/2019 Non-covered Recipient Entity
OLYMPIAN CLINICAL RSRCH
Adjunctive Computerized Cognitive Training (CCT) No dispute reported 06/30/2026 703922815
Principal investigator 1 Avanir Pharmaceuticals, Inc. $2,732.57 09/27/2019 Non-covered Recipient Entity
OLYMPIAN CLINICAL RESEARCH
15-AVP-786-303 No dispute reported 06/30/2026 656018069
Principal investigator 1 Allergan Inc. $1,000.00 09/24/2019 Non-covered Recipient Entity
OLYMPIAN CLINICAL RESEARCH
AN OPEN LABEL, LONG TERM SAFETY STUDY OF RAPASTINEL AS AN ADJUNCTIVE THERAPY IN PATIENTS WITH MAJOR DEPRESSIVE DISORDER MDD. No dispute reported 06/30/2026 670079627
Principal investigator 1 Janssen Research & Development, LLC $4,271.00 09/23/2019 Non-covered Recipient Entity
ACADEMIC ALLIANCE IN DERMATOLOGY
A Phase 2, Multicenter, Randomized, Placebo-Controlled, Double-Blind, Proof-of-Concept Study to Evaluate Guselkumab for the Treatment of Subjects with Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 654241475
Principal investigator 1 Allergan Inc. $950.00 09/13/2019 Non-covered Recipient Entity
ACADEMIC ALLIANCE IN DERMATOLOGY OLYMPIAN CLINICA
A DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF CARIPRAZINE AS ADJUNCTIVE THERAPY IN MAJOR DEPRESSIVE DISORDER No dispute reported 06/30/2026 670075365
Principal investigator 1 AbbVie, Inc. $19,170.24 09/12/2019 Non-covered Recipient Entity
ACADEMIC ALLIANCE IN DERMATOLOGY, INC.
M16-045 No dispute reported 06/30/2026 647590355
Principal investigator 1 AbbVie, Inc. $13,983.12 09/12/2019 Non-covered Recipient Entity
ACADEMIC ALLIANCE IN DERMATOLOGY, INC.
M16-045 No dispute reported 06/30/2026 647590357
Principal investigator 1 Janssen Research & Development, LLC $1,853.75 09/05/2019 Non-covered Recipient Entity
ACADEMIC ALLIANCE IN DERMATOLOGY
A Prospective, Matched-Control, Randomized, Open-Label, Flexible-Dose, Study in Subjects With Recent-Onset Schizophrenia or Schizophreniform Disorder to Compare Disease Progression and Disease Modification Following Treatment With Paliperidone Palmitate Long-Acting Injection or Oral Antipsychotics No dispute reported 06/30/2026 654241437
Principal investigator 1 Boehringer Ingelheim International GmbH $35.00 09/01/2019 Non-covered Recipient Entity
OLYMPIAN CLINICAL RSRCH
Adjunctive Computerized Cognitive Training (CCT) No dispute reported 06/30/2026 703921909
Principal investigator 1 Eisai Inc. $3,802.00 08/27/2019 Non-covered Recipient Entity
ACADEMIC ALLIANCE IN DERMATOLOGY
A Placebo-Controlled, Double-Blind, Parallel-Group, 24 Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702536227
Principal investigator 1 Allergan Inc. $950.00 08/23/2019 Non-covered Recipient Entity
ACADEMIC ALLIANCE IN DERMATOLOGY OLYMPIAN CLINICA
A DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF CARIPRAZINE AS ADJUNCTIVE THERAPY IN MAJOR DEPRESSIVE DISORDER No dispute reported 06/30/2026 670068945
Principal investigator 1 Allergan Inc. $2,348.05 08/22/2019 Non-covered Recipient Entity
OLYMPIAN CLINICAL RESEARCH
AN OPEN LABEL, LONG TERM SAFETY STUDY OF RAPASTINEL AS AN ADJUNCTIVE THERAPY IN PATIENTS WITH MAJOR DEPRESSIVE DISORDER MDD. No dispute reported 06/30/2026 670067831
Principal investigator 1 Avanir Pharmaceuticals, Inc. $12,984.65 08/22/2019 Non-covered Recipient Entity
OLYMPIAN CLINICAL RESEARCH
15-AVP-786-303 No dispute reported 06/30/2026 656018067
Principal investigator 1 AbbVie, Inc. $21,675.00 08/20/2019 Non-covered Recipient Entity
ACADEMIC ALLIANCE IN DERMATOLOGY, INC.
M16-045 No dispute reported 06/30/2026 647590353
Principal investigator 1 Janssen Research & Development, LLC $7,850.00 08/19/2019 Non-covered Recipient Entity
ACADEMIC ALLIANCE IN DERMATOLOGY
A Phase 2, Multicenter, Randomized, Placebo-Controlled, Double-Blind, Proof-of-Concept Study to Evaluate Guselkumab for the Treatment of Subjects with Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 654241473
Principal investigator 1 Eisai Inc. $2,361.00 08/15/2019 Non-covered Recipient Entity
ACADEMIC ALLIANCE IN DERMATOLOGY
A Placebo-Controlled, Double-Blind, Parallel-Group, 24 Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702536229
Principal investigator 1 Eisai Inc. $2,533.00 08/15/2019 Non-covered Recipient Entity
ACADEMIC ALLIANCE IN DERMATOLOGY
A Placebo-Controlled, Double-Blind, Parallel-Group, 24 Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702536231
Principal investigator 1 Otsuka Pharmaceutical Development & Commercialization, Inc. $26,957.00 08/08/2019 Non-covered Recipient Entity
ACADEMIC ALLIANCE IN DERMATOLOGY
AN OPEN-LABEL, 52-WEEK, MULTICENTER TRIAL EVALUATING THE LONG-TERM SAFETY AND TOLERABILITY OF CENTANAFADINE SUSTAINED-RELEASE TABLETS IN ADULTS WITH ATTENTION-DEFICITHYPERACTIVITY DISORDER No dispute reported 06/30/2026 696054847
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $3,580.00 08/07/2019 Non-covered Recipient Entity
ACADEMIC ALLICANCE IN DERMATOLOGY INC
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Risperidone Extended-Release Injectable Suspension (TV-46000) for Subcutaneous Use as Maintenance Treatment in Adult and Adolescent Patients With Schizophrenia No dispute reported 06/30/2026 685010044
Principal investigator 1 Boehringer Ingelheim International GmbH $35.00 08/01/2019 Non-covered Recipient Entity
OLYMPIAN CLINICAL RSRCH
Adjunctive Computerized Cognitive Training (CCT) No dispute reported 06/30/2026 703921085
Principal investigator 1 AbbVie, Inc. $3,349.43 07/30/2019 Non-covered Recipient Entity
ACADEMIC ALLIANCE IN DERMATOLOGY, INC.
M16-045 No dispute reported 06/30/2026 647590381
Principal investigator 1 Janssen Research & Development, LLC $2,648.75 07/29/2019 Non-covered Recipient Entity
ACADEMIC ALLIANCE IN DERMATOLOGY
A Prospective, Matched-Control, Randomized, Open-Label, Flexible-Dose, Study in Subjects With Recent-Onset Schizophrenia or Schizophreniform Disorder to Compare Disease Progression and Disease Modification Following Treatment With Paliperidone Palmitate Long-Acting Injection or Oral Antipsychotics No dispute reported 06/30/2026 654241435
Principal investigator 1 AbbVie, Inc. $500.00 07/22/2019 Non-covered Recipient Entity
ACADEMIC ALLIANCE IN DERMATOLOGY, INC.
M16-045 No dispute reported 06/30/2026 647590383
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $13,340.00 07/22/2019 Non-covered Recipient Entity
Academic Alliance in Dermatology
Adjunctive Computerized Cognitive Training CCT No dispute reported 06/30/2026 704143347
Principal investigator 1 Janssen Research & Development, LLC $6,469.00 07/22/2019 Non-covered Recipient Entity
ACADEMIC ALLIANCE IN DERMATOLOGY
A Phase 2, Multicenter, Randomized, Placebo-Controlled, Double-Blind, Proof-of-Concept Study to Evaluate Guselkumab for the Treatment of Subjects with Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 654241471
Principal investigator 1 Janssen Research & Development, LLC $520.00 07/18/2019 Non-covered Recipient Entity
ACADEMIC ALLIANCE IN DERMATOLOGY
A Phase 2a Randomized, Double-blind, Placebo-Controlled, Parallel-Group, Multi-center Study Investigating the Efficacy, Safety, Tolerability and Pharmacokinetics of JNJ67953964 in Subjects with Major Depressive Disorder. No dispute reported 06/30/2026 654241469
Principal investigator 1 Allergan Inc. $1,000.00 07/11/2019 Non-covered Recipient Entity
OLYMPIAN CLINICAL RESEARCH
A RANDOMIZED, DOUBLE-BLIND, PLACEBO CONTROLLED, MULTICENTER STUDY OF RAPASTINEL AS ADJUNCTIVE THERAPY IN THE PREVENTION OF RELAPSE IN PATIENTS WITH MAJOR DEPRESSIVE DISORDER No dispute reported 06/30/2026 670056447
Principal investigator 1 Allergan Inc. $750.00 07/09/2019 Non-covered Recipient Entity
OLYMPIAN CLINICAL RESEARCH
A DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF CARIPRAZINE AS ADJUNCTIVE THERAPY IN MAJOR DEPRESSIVE DISORDER No dispute reported 06/30/2026 670055815
Principal investigator 1 Alkermes, Inc. $1,391.40 07/08/2019 Non-covered Recipient Entity
OLYMPIAN CLINICAL RESEARCH
A Phase 3 Study to Evaluate Weight Gain of ALKS 3831 Compared to OLANZAPINE in Adults with Schizophrenia No dispute reported 06/30/2026 653533199
Principal investigator 1 Boehringer Ingelheim International GmbH $35.00 07/01/2019 Non-covered Recipient Entity
OLYMPIAN CLINICAL RSRCH
Adjunctive Computerized Cognitive Training (CCT) No dispute reported 06/30/2026 703917773
Principal investigator 1 Janssen Research & Development, LLC $5,018.00 06/28/2019 Non-covered Recipient Entity
ACADEMIC ALLIANCE IN DERMATOLOGY
A Phase 2, Multicenter, Randomized, Placebo-Controlled, Double-Blind, Proof-of-Concept Study to Evaluate Guselkumab for the Treatment of Subjects with Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 654241465
Principal investigator 1 AbbVie, Inc. $9,765.17 06/27/2019 Non-covered Recipient Entity
ACADEMIC ALLIANCE IN DERMATOLOGY, INC.
M16-045 No dispute reported 06/30/2026 647590379
Principal investigator 1 Eisai Inc. $75.00 06/27/2019 Non-covered Recipient Entity
ACADEMIC ALLIANCE IN DERMATOLOGY
A Placebo-Controlled, Double-Blind, Parallel-Group, 24 Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702536235
Principal investigator 1 Eli Lilly and Company $2,500.00 06/11/2019 Non-covered Recipient Entity
ACADEMIC ALLIANCE IN DERMATOLOGY
A MULTICENTER, RANDOMIZED, DOUBLE-BLIND STUDY COMPARING THE EFFICACY AND SAFETY OF IXEKIZUMAB VERSUS PLACEBO IN PATIENTS WITH MODERATE-TO-SEVERE GENITAL PSORIASIS No dispute reported 06/30/2026 654287317
Principal investigator 1 Allergan Inc. $4,200.00 06/06/2019 Non-covered Recipient Entity
OLYMPIAN CLINICAL RESEARCH
A RANDOMIZED, DOUBLE-BLIND, PLACEBO CONTROLLED, MULTICENTER STUDY OF RAPASTINEL AS ADJUNCTIVE THERAPY IN THE PREVENTION OF RELAPSE IN PATIENTS WITH MAJOR DEPRESSIVE DISORDER No dispute reported 06/30/2026 670050717
Principal investigator 1 Neurocrine Biosciences, Inc. $125.00 06/06/2019 Non-covered Recipient Entity
OLYMPIAN CLINICAL RESEARCH
OPEN-LABEL SAFETY AND TOLERABILITY STUDY OF NBI-98854 FOR THE TREATMENT OF PEDIATRIC SUBJECTS WITH TOURETTE SYNDROME No dispute reported 06/30/2026 686566369
Principal investigator 1 Boehringer Ingelheim International GmbH $35.00 06/01/2019 Non-covered Recipient Entity
OLYMPIAN CLINICAL RSRCH
Adjunctive Computerized Cognitive Training (CCT) No dispute reported 06/30/2026 703912403
Principal investigator 1 Allergan Inc. $2,000.00 05/30/2019 Non-covered Recipient Entity
OLYMPIAN CLINICAL RESEARCH
A DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF CARIPRAZINE AS ADJUNCTIVE THERAPY IN MAJOR DEPRESSIVE DISORDER No dispute reported 06/30/2026 670049717
Principal investigator 1 Eisai Inc. $3,944.00 05/30/2019 Non-covered Recipient Entity
ACADEMIC ALLIANCE IN DERMATOLOGY
A Placebo-Controlled, Double-Blind, Parallel-Group, 24 Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702536237
Principal investigator 1 AbbVie, Inc. $3,092.57 05/29/2019 Non-covered Recipient Entity
ACADEMIC ALLIANCE IN DERMATOLOGY, INC.
M16-045 No dispute reported 06/30/2026 647590375
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $500.00 05/29/2019 Non-covered Recipient Entity
ACADEMIC ALLICANCE IN DERMATOLOGY INC
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Risperidone Extended-Release Injectable Suspension (TV-46000) for Subcutaneous Use as Maintenance Treatment in Adult and Adolescent Patients With Schizophrenia No dispute reported 06/30/2026 685007475
Principal investigator 1 Janssen Research & Development, LLC $1,081.75 05/27/2019 Non-covered Recipient Entity
ACADEMIC ALLIANCE IN DERMATOLOGY
A Prospective, Matched-Control, Randomized, Open-Label, Flexible-Dose, Study in Subjects With Recent-Onset Schizophrenia or Schizophreniform Disorder to Compare Disease Progression and Disease Modification Following Treatment With Paliperidone Palmitate Long-Acting Injection or Oral Antipsychotics No dispute reported 06/30/2026 654241433
Principal investigator 1 Janssen Research & Development, LLC $5,635.00 05/24/2019 Non-covered Recipient Entity
ACADEMIC ALLIANCE IN DERMATOLOGY
A Phase 2, Multicenter, Randomized, Placebo-Controlled, Double-Blind, Proof-of-Concept Study to Evaluate Guselkumab for the Treatment of Subjects with Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 654241467
Principal investigator 1 Avanir Pharmaceuticals, Inc. $2,500.00 05/23/2019 Non-covered Recipient Entity
OLYMPIAN CLINICAL RESEARCH
15-AVP-786-301 No dispute reported 06/30/2026 656018065
Principal investigator 1 Allergan Inc. $500.00 05/21/2019 Non-covered Recipient Entity
OLYMPIAN CLINICAL RESEARCH
A DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF CARIPRAZINE AS ADJUNCTIVE THERAPY IN MAJOR DEPRESSIVE DISORDER No dispute reported 06/30/2026 670047257
Principal investigator 1 AbbVie, Inc. $150.00 05/15/2019 Non-covered Recipient Entity
ACADEMIC ALLIANCE IN DERMATOLOGY, INC.
M16-045 No dispute reported 06/30/2026 647590377
Principal investigator 1 Eisai Inc. $75.00 05/07/2019 Non-covered Recipient Entity
ACADEMIC ALLIANCE IN DERMATOLOGY
A Placebo-Controlled, Double-Blind, Parallel-Group, 24 Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702536233
Principal investigator 1 Neurocrine Biosciences, Inc. $203.00 05/02/2019 Non-covered Recipient Entity
OLYMPIAN CLINICAL RESEARCH
OPEN-LABEL SAFETY AND TOLERABILITY STUDY OF NBI-98854 FOR THE TREATMENT OF PEDIATRIC SUBJECTS WITH TOURETTE SYNDROME No dispute reported 06/30/2026 686565849
Principal investigator 1 Boehringer Ingelheim International GmbH $35.00 05/01/2019 Non-covered Recipient Entity
OLYMPIAN CLINICAL RSRCH
Adjunctive Computerized Cognitive Training (CCT) No dispute reported 06/30/2026 703912249
Principal investigator 1 Boehringer Ingelheim International GmbH $80.00 05/01/2019 Non-covered Recipient Entity
OLYMPIAN CLINICAL RSRCH
Adjunctive Computerized Cognitive Training (CCT) No dispute reported 06/30/2026 703912325
Principal investigator 1 Boehringer Ingelheim International GmbH $12.50 05/01/2019 Non-covered Recipient Entity
OLYMPIAN CLINICAL RSRCH
Adjunctive Computerized Cognitive Training (CCT) No dispute reported 06/30/2026 703912335
Principal investigator 1 AbbVie, Inc. $2,910.81 04/29/2019 Non-covered Recipient Entity
ACADEMIC ALLIANCE IN DERMATOLOGY, INC.
M16-045 No dispute reported 06/30/2026 647590373
Principal investigator 1 Janssen Research & Development, LLC $1,932.50 04/26/2019 Non-covered Recipient Entity
ACADEMIC ALLIANCE IN DERMATOLOGY
A Prospective, Matched-Control, Randomized, Open-Label, Flexible-Dose, Study in Subjects With Recent-Onset Schizophrenia or Schizophreniform Disorder to Compare Disease Progression and Disease Modification Following Treatment With Paliperidone Palmitate Long-Acting Injection or Oral Antipsychotics No dispute reported 06/30/2026 654241429
Principal investigator 1 Janssen Research & Development, LLC $706.00 04/26/2019 Non-covered Recipient Entity
ACADEMIC ALLIANCE IN DERMATOLOGY
A Phase 2a Randomized, Double-blind, Placebo-Controlled, Parallel-Group, Multi-center Study Investigating the Efficacy, Safety, Tolerability and Pharmacokinetics of JNJ67953964 in Subjects with Major Depressive Disorder. No dispute reported 06/30/2026 654241463
Principal investigator 1 Avanir Pharmaceuticals, Inc. $1,306.25 04/25/2019 Non-covered Recipient Entity
OLYMPIAN CLINICAL RESEARCH
15-AVP-786-301 No dispute reported 06/30/2026 656018059
Principal investigator 1 Avanir Pharmaceuticals, Inc. $6,275.00 04/25/2019 Non-covered Recipient Entity
OLYMPIAN CLINICAL RESEARCH
15-AVP-786-301 No dispute reported 06/30/2026 656018061
Principal investigator 1 Boehringer Ingelheim International GmbH $950.98 04/25/2019 Non-covered Recipient Entity
OLYMPIAN CLINICAL RSRCH
Adjunctive Computerized Cognitive Training (CCT) No dispute reported 06/30/2026 703912363
Principal investigator 1 Eli Lilly and Company $265.10 04/25/2019 Non-covered Recipient Entity
PRES AND DIR GEORGETOWN COLLEGE FOR GRGTWN UNIV
A 24-WEEK MULTICENTER, RANDOMIZED, BLINDED, PARALLEL-GROUP STUDY COMPARING THE EFFICACY AND SAFETY OF IXEKIZUMAB TO GUSELKUMAB IN PATIENTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS No dispute reported 06/30/2026 654290361
Principal investigator 1 Neurocrine Biosciences, Inc. $1,000.00 04/25/2019 Non-covered Recipient Entity
OLYMPIAN CLINICAL RESEARCH
SAFETY, TOLERABILITY, AND EFFICACY OF NBI-98854 FOR THE TREATMENT OF PEDIATRIC SUBJECTS WITH TOURETTE SYNDROME No dispute reported 06/30/2026 686565743
Principal investigator 1 Otsuka Pharmaceutical Development & Commercialization, Inc. $65,504.45 04/25/2019 Non-covered Recipient Entity
ACADEMIC ALLIANCE IN DERMATOLOGY
A PHASE 3, RANDOMIZED, DOUBLE-BLIND, MULTICENTER, PLACEBO-CONTROLLED, PARALLEL-GROUP TRIAL EVALUATING THE EFFICACY, SAFETY, AND TOLERABILITY OF CENTANAFADINE SUSTAINED-RELEASE TABLETS IN ADULTS WITH ATTENTION-DEFICITHYPERACTIVITY DISORDER TRIAL 405-201-00014 No dispute reported 06/30/2026 696054248
Principal investigator 1 Janssen Research & Development, LLC $19,485.00 04/22/2019 Non-covered Recipient Entity
ACADEMIC ALLIANCE IN DERMATOLOGY
A Phase 2, Multicenter, Randomized, Placebo-Controlled, Double-Blind, Proof-of-Concept Study to Evaluate Guselkumab for the Treatment of Subjects with Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 654241461
Principal investigator 1 Neurocrine Biosciences, Inc. $6,874.51 04/11/2019 Non-covered Recipient Entity
OLYMPIAN CLINICAL RESEARCH
SAFETY, TOLERABILITY, AND EFFICACY OF NBI-98854 FOR THE TREATMENT OF PEDIATRIC SUBJECTS WITH TOURETTE SYNDROME No dispute reported 06/30/2026 686565707
Principal investigator 1 Boehringer Ingelheim International GmbH $1,239.77 04/10/2019 Non-covered Recipient Entity
OLYMPIAN CLINICAL RSRCH
Adjunctive Computerized Cognitive Training (CCT) No dispute reported 06/30/2026 703925721
Principal investigator 1 Boehringer Ingelheim International GmbH $1,234.43 04/08/2019 Non-covered Recipient Entity
OLYMPIAN CLINICAL RSRCH
Adjunctive Computerized Cognitive Training (CCT) No dispute reported 06/30/2026 703925719
Principal investigator 1 Janssen Research & Development, LLC $133.75 04/08/2019 Non-covered Recipient Entity
ACADEMIC ALLIANCE IN DERMATOLOGY
A Prospective, Matched-Control, Randomized, Open-Label, Flexible-Dose, Study in Subjects With Recent-Onset Schizophrenia or Schizophreniform Disorder to Compare Disease Progression and Disease Modification Following Treatment With Paliperidone Palmitate Long-Acting Injection or Oral Antipsychotics No dispute reported 06/30/2026 654241431
Principal investigator 1 Eisai Inc. $2,179.00 04/04/2019 Non-covered Recipient Entity
ACADEMIC ALLIANCE IN DERMATOLOGY
A Placebo-Controlled, Double-Blind, Parallel-Group, 24 Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702536239
Principal investigator 1 Eisai Inc. $1,421.00 04/04/2019 Non-covered Recipient Entity
ACADEMIC ALLIANCE IN DERMATOLOGY
A Placebo-Controlled, Double-Blind, Parallel-Group, 24 Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702536241
Principal investigator 1 Eisai Inc. $1,032.00 04/04/2019 Non-covered Recipient Entity
ACADEMIC ALLIANCE IN DERMATOLOGY
A Placebo-Controlled, Double-Blind, Parallel-Group, 24 Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702536243
Principal investigator 1 Neurocrine Biosciences, Inc. $2,002.55 04/04/2019 Non-covered Recipient Entity
OLYMPIAN CLINICAL RESEARCH
OPEN-LABEL SAFETY AND TOLERABILITY STUDY OF NBI-98854 FOR THE TREATMENT OF PEDIATRIC SUBJECTS WITH TOURETTE SYNDROME No dispute reported 06/30/2026 686565415
Principal investigator 1 Boehringer Ingelheim International GmbH $905.86 04/02/2019 Non-covered Recipient Entity
OLYMPIAN CLINICAL RSRCH
BI 425809 Adjunctive Computerized Cognitive Training (CCT) No dispute reported 06/30/2026 708445811
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $991.56 04/02/2019 Non-covered Recipient Entity
OLYMPIAN CLINICAL RSRCH
Adjunctive Computerized Cognitive Training CCT No dispute reported 06/30/2026 704143501
Principal investigator 1 AbbVie, Inc. $2,293.78 03/29/2019 Non-covered Recipient Entity
ACADEMIC ALLIANCE IN DERMATOLOGY, INC.
M16-045 No dispute reported 06/30/2026 647590371
Principal investigator 1 Alkermes, Inc. $500.00 03/28/2019 Non-covered Recipient Entity
OLYMPIAN CLINICAL RESEARCH
A Phase 3 Study to Evaluate Weight Gain of ALKS 3831 Compared to OLANZAPINE in Adults with Schizophrenia No dispute reported 06/30/2026 653533197
Principal investigator 1 Neurocrine Biosciences, Inc. $4,193.73 03/28/2019 Non-covered Recipient Entity
OLYMPIAN CLINICAL RESEARCH
OPEN-LABEL SAFETY AND TOLERABILITY STUDY OF NBI-98854 FOR THE TREATMENT OF PEDIATRIC SUBJECTS WITH TOURETTE SYNDROME No dispute reported 06/30/2026 686565305
Principal investigator 1 Eli Lilly and Company $11,284.00 03/18/2019 Non-covered Recipient Entity
ACADEMIC ALLIANCE IN DERMATOLOGY
A 24-WEEK MULTICENTER, RANDOMIZED, BLINDED, PARALLEL-GROUP STUDY COMPARING THE EFFICACY AND SAFETY OF IXEKIZUMAB TO GUSELKUMAB IN PATIENTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS No dispute reported 06/30/2026 654287199
Principal investigator 1 Janssen Research & Development, LLC $2,356.00 03/18/2019 Non-covered Recipient Entity
ACADEMIC ALLIANCE IN DERMATOLOGY
A Phase 2, Multicenter, Randomized, Placebo-Controlled, Double-Blind, Proof-of-Concept Study to Evaluate Guselkumab for the Treatment of Subjects with Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 654241455
Principal investigator 1 Allergan Inc. $4,450.00 03/14/2019 Non-covered Recipient Entity
OLYMPIAN CLINICAL RESEARCH
A RANDOMIZED, DOUBLE-BLIND, PLACEBO CONTROLLED, MULTICENTER STUDY OF RAPASTINEL AS ADJUNCTIVE THERAPY IN THE PREVENTION OF RELAPSE IN PATIENTS WITH MAJOR DEPRESSIVE DISORDER No dispute reported 06/30/2026 670030483
Principal investigator 1 Eisai Inc. $1,413.00 03/12/2019 Non-covered Recipient Entity
ACADEMIC ALLIANCE IN DERMATOLOGY
A Placebo-Controlled, Double-Blind, Parallel-Group, 24 Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702536191
Principal investigator 1 Eisai Inc. $811.00 03/12/2019 Non-covered Recipient Entity
ACADEMIC ALLIANCE IN DERMATOLOGY
A Placebo-Controlled, Double-Blind, Parallel-Group, 24 Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702536193
Principal investigator 1 Eisai Inc. $1,413.00 03/12/2019 Non-covered Recipient Entity
ACADEMIC ALLIANCE IN DERMATOLOGY
A Placebo-Controlled, Double-Blind, Parallel-Group, 24 Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702536195
Principal investigator 1 Eisai Inc. $811.00 03/12/2019 Non-covered Recipient Entity
ACADEMIC ALLIANCE IN DERMATOLOGY
A Placebo-Controlled, Double-Blind, Parallel-Group, 24 Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702536197
Principal investigator 1 Eisai Inc. $1,570.00 03/12/2019 Non-covered Recipient Entity
ACADEMIC ALLIANCE IN DERMATOLOGY
A Placebo-Controlled, Double-Blind, Parallel-Group, 24 Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702536199
Principal investigator 1 Eisai Inc. $75.00 03/12/2019 Non-covered Recipient Entity
ACADEMIC ALLIANCE IN DERMATOLOGY
A Placebo-Controlled, Double-Blind, Parallel-Group, 24 Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702536201
Principal investigator 1 Eisai Inc. $2,361.00 03/12/2019 Non-covered Recipient Entity
ACADEMIC ALLIANCE IN DERMATOLOGY
A Placebo-Controlled, Double-Blind, Parallel-Group, 24 Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702536203
Principal investigator 1 Eisai Inc. $3,802.00 03/12/2019 Non-covered Recipient Entity
ACADEMIC ALLIANCE IN DERMATOLOGY
A Placebo-Controlled, Double-Blind, Parallel-Group, 24 Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702536205
Principal investigator 1 Eisai Inc. $3,802.00 03/12/2019 Non-covered Recipient Entity
ACADEMIC ALLIANCE IN DERMATOLOGY
A Placebo-Controlled, Double-Blind, Parallel-Group, 24 Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702536207
Principal investigator 1 Eisai Inc. $1,896.00 03/12/2019 Non-covered Recipient Entity
ACADEMIC ALLIANCE IN DERMATOLOGY
A Placebo-Controlled, Double-Blind, Parallel-Group, 24 Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702536209
Principal investigator 1 Eisai Inc. $1,570.00 03/12/2019 Non-covered Recipient Entity
ACADEMIC ALLIANCE IN DERMATOLOGY
A Placebo-Controlled, Double-Blind, Parallel-Group, 24 Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702536211
Principal investigator 1 Eisai Inc. $75.00 03/12/2019 Non-covered Recipient Entity
ACADEMIC ALLIANCE IN DERMATOLOGY
A Placebo-Controlled, Double-Blind, Parallel-Group, 24 Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702536213
Principal investigator 1 Eisai Inc. $516.00 03/12/2019 Non-covered Recipient Entity
ACADEMIC ALLIANCE IN DERMATOLOGY
A Placebo-Controlled, Double-Blind, Parallel-Group, 24 Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702536215
Principal investigator 1 Eisai Inc. $75.00 03/12/2019 Non-covered Recipient Entity
ACADEMIC ALLIANCE IN DERMATOLOGY
A Placebo-Controlled, Double-Blind, Parallel-Group, 24 Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702536217
Principal investigator 1 Eisai Inc. $329.00 03/12/2019 Non-covered Recipient Entity
ACADEMIC ALLIANCE IN DERMATOLOGY
A Placebo-Controlled, Double-Blind, Parallel-Group, 24 Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702536219
Principal investigator 1 Eisai Inc. $75.00 03/12/2019 Non-covered Recipient Entity
ACADEMIC ALLIANCE IN DERMATOLOGY
A Placebo-Controlled, Double-Blind, Parallel-Group, 24 Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702536221
Principal investigator 1 Eisai Inc. $329.00 03/12/2019 Non-covered Recipient Entity
ACADEMIC ALLIANCE IN DERMATOLOGY
A Placebo-Controlled, Double-Blind, Parallel-Group, 24 Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702536223
Principal investigator 1 Eisai Inc. $75.00 03/12/2019 Non-covered Recipient Entity
ACADEMIC ALLIANCE IN DERMATOLOGY
A Placebo-Controlled, Double-Blind, Parallel-Group, 24 Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702536225
Principal investigator 1 Eli Lilly and Company $7,728.00 03/07/2019 Non-covered Recipient Entity
ACADEMIC ALLIANCE IN DERMATOLOGY
A 24-MONTH, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP, EFFICACY, SAFETY, TOLERABILITY, BIOMARKER, AND PHARMACOKINETIC STUDY OF AZD3293 IN EARLY ALZHEIMERS DISEASE -THE AMARANTH STUDY No dispute reported 06/30/2026 654287281
Principal investigator 1 Otsuka Pharmaceutical Development & Commercialization, Inc. $6,945.36 03/07/2019 Non-covered Recipient Entity
ACADEMIC ALLIANCE IN DERMATOLOGY
PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO- AND ACTIVE-CONTROLLED TRIAL OF BREXPIPRAZOLE 1 - 3 MGDAY AS MONOTHERAPY OR AS COMBINATION THERAPY IN THE TREATMENT OF ADULTS WITH POST-TRAUMATIC STRESS DISORDER No dispute reported 06/30/2026 696053541
Principal investigator 1 Janssen Research & Development, LLC $2,110.00 03/04/2019 Non-covered Recipient Entity
ACADEMIC ALLIANCE IN DERMATOLOGY
A Prospective, Matched-Control, Randomized, Open-Label, Flexible-Dose, Study in Subjects With Recent-Onset Schizophrenia or Schizophreniform Disorder to Compare Disease Progression and Disease Modification Following Treatment With Paliperidone Palmitate Long-Acting Injection or Oral Antipsychotics No dispute reported 06/30/2026 654241425
Principal investigator 1 AbbVie, Inc. $15,726.17 02/28/2019 Non-covered Recipient Entity
ACADEMIC ALLIANCE IN DERMATOLOGY, INC.
M16-045 No dispute reported 06/30/2026 647590369
Principal investigator 1 Eli Lilly and Company $22.36 02/21/2019 Non-covered Recipient Entity
ACADEMIC ALLIANCE IN DERMATOLOGY
A 24-WEEK MULTICENTER, RANDOMIZED, BLINDED, PARALLEL-GROUP STUDY COMPARING THE EFFICACY AND SAFETY OF IXEKIZUMAB TO GUSELKUMAB IN PATIENTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS No dispute reported 06/30/2026 654287201
Principal investigator 1 Neurocrine Biosciences, Inc. $203.00 02/21/2019 Non-covered Recipient Entity
OLYMPIAN CLINICAL RESEARCH
SAFETY, TOLERABILITY, AND EFFICACY OF NBI-98854 FOR THE TREATMENT OF PEDIATRIC SUBJECTS WITH TOURETTE SYNDROME No dispute reported 06/30/2026 686564663
Principal investigator 1 AbbVie, Inc. $5,000.00 02/19/2019 Non-covered Recipient Entity
ACADEMIC ALLIANCE IN DERMATOLOGY, INC.
M16-045 No dispute reported 06/30/2026 647590367
Principal investigator 1 Janssen Research & Development, LLC $11,701.00 02/18/2019 Non-covered Recipient Entity
ACADEMIC ALLIANCE IN DERMATOLOGY
A Phase 2, Multicenter, Randomized, Placebo-Controlled, Double-Blind, Proof-of-Concept Study to Evaluate Guselkumab for the Treatment of Subjects with Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 654241453
Principal investigator 1 Janssen Research & Development, LLC $5,000.00 02/15/2019 Non-covered Recipient Entity
ACADEMIC ALLIANCE IN DERMATOLOGY
A Phase 2a Randomized, Double-blind, Placebo-Controlled, Parallel-Group, Multi-center Study Investigating the Efficacy, Safety, Tolerability and Pharmacokinetics of JNJ67953964 in Subjects with Major Depressive Disorder. No dispute reported 06/30/2026 654241447
Principal investigator 1 Janssen Research & Development, LLC $6,554.00 02/15/2019 Non-covered Recipient Entity
ACADEMIC ALLIANCE IN DERMATOLOGY
A Double-blind, Randomized, Active-controlled, Parallel-group Study of Paliperidone Palmitate 6-Month Formulation No dispute reported 06/30/2026 654241449
Principal investigator 1 Neurocrine Biosciences, Inc. $5,701.10 02/07/2019 Non-covered Recipient Entity
OLYMPIAN CLINICAL RESEARCH
OPEN-LABEL SAFETY AND TOLERABILITY STUDY OF NBI-98854 FOR THE TREATMENT OF PEDIATRIC SUBJECTS WITH TOURETTE SYNDROME No dispute reported 06/30/2026 686564435
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $3,285.00 02/06/2019 Non-covered Recipient Entity
ACADEMIC ALLICANCE IN DERMATOLOGY INC
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Risperidone Extended-Release Injectable Suspension (TV-46000) for Subcutaneous Use as Maintenance Treatment in Adult and Adolescent Patients With Schizophrenia No dispute reported 06/30/2026 685006307
Principal investigator 1 Avanir Pharmaceuticals, Inc. $2,031.25 01/31/2019 Non-covered Recipient Entity
OLYMPIAN CLINICAL RESEARCH
15-AVP-786-301 No dispute reported 06/30/2026 656018057
Principal investigator 1 Neurocrine Biosciences, Inc. $5.18 01/31/2019 Non-covered Recipient Entity
OLYMPIAN CLINICAL RESEARCH
OPEN-LABEL SAFETY AND TOLERABILITY STUDY OF NBI-98854 FOR THE TREATMENT OF PEDIATRIC SUBJECTS WITH TOURETTE SYNDROME No dispute reported 06/30/2026 686563999
Principal investigator 1 Neurocrine Biosciences, Inc. $5.18 01/31/2019 Non-covered Recipient Entity
OLYMPIAN CLINICAL RESEARCH
SAFETY, TOLERABILITY, AND EFFICACY OF NBI-98854 FOR THE TREATMENT OF PEDIATRIC SUBJECTS WITH TOURETTE SYNDROME No dispute reported 06/30/2026 686564043
Principal investigator 1 Janssen Research & Development, LLC $2,492.50 01/25/2019 Non-covered Recipient Entity
ACADEMIC ALLIANCE IN DERMATOLOGY
A Prospective, Matched-Control, Randomized, Open-Label, Flexible-Dose, Study in Subjects With Recent-Onset Schizophrenia or Schizophreniform Disorder to Compare Disease Progression and Disease Modification Following Treatment With Paliperidone Palmitate Long-Acting Injection or Oral Antipsychotics No dispute reported 06/30/2026 654241427
Principal investigator 1 Eisai Inc. $1,413.00 01/24/2019 Non-covered Recipient Entity
ACADEMIC ALLIANCE IN DERMATOLOGY
A Placebo-Controlled, Double-Blind, Parallel-Group, 24 Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702536167
Principal investigator 1 Eisai Inc. $75.00 01/24/2019 Non-covered Recipient Entity
ACADEMIC ALLIANCE IN DERMATOLOGY
A Placebo-Controlled, Double-Blind, Parallel-Group, 24 Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702536169
Principal investigator 1 Eisai Inc. $3,802.00 01/24/2019 Non-covered Recipient Entity
ACADEMIC ALLIANCE IN DERMATOLOGY
A Placebo-Controlled, Double-Blind, Parallel-Group, 24 Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702536171
Principal investigator 1 Eisai Inc. $2,794.00 01/24/2019 Non-covered Recipient Entity
ACADEMIC ALLIANCE IN DERMATOLOGY
A Placebo-Controlled, Double-Blind, Parallel-Group, 24 Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702536173
Principal investigator 1 Eisai Inc. $811.00 01/24/2019 Non-covered Recipient Entity
ACADEMIC ALLIANCE IN DERMATOLOGY
A Placebo-Controlled, Double-Blind, Parallel-Group, 24 Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702536175
Principal investigator 1 Eisai Inc. $1,570.00 01/24/2019 Non-covered Recipient Entity
ACADEMIC ALLIANCE IN DERMATOLOGY
A Placebo-Controlled, Double-Blind, Parallel-Group, 24 Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702536177
Principal investigator 1 Eisai Inc. $75.00 01/24/2019 Non-covered Recipient Entity
ACADEMIC ALLIANCE IN DERMATOLOGY
A Placebo-Controlled, Double-Blind, Parallel-Group, 24 Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702536179
Principal investigator 1 Eisai Inc. $516.00 01/24/2019 Non-covered Recipient Entity
ACADEMIC ALLIANCE IN DERMATOLOGY
A Placebo-Controlled, Double-Blind, Parallel-Group, 24 Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702536181
Principal investigator 1 Eisai Inc. $75.00 01/24/2019 Non-covered Recipient Entity
ACADEMIC ALLIANCE IN DERMATOLOGY
A Placebo-Controlled, Double-Blind, Parallel-Group, 24 Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702536183
Principal investigator 1 Eisai Inc. $329.00 01/24/2019 Non-covered Recipient Entity
ACADEMIC ALLIANCE IN DERMATOLOGY
A Placebo-Controlled, Double-Blind, Parallel-Group, 24 Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702536185
Principal investigator 1 Eisai Inc. $75.00 01/24/2019 Non-covered Recipient Entity
ACADEMIC ALLIANCE IN DERMATOLOGY
A Placebo-Controlled, Double-Blind, Parallel-Group, 24 Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702536187
Principal investigator 1 Eisai Inc. $2,361.00 01/24/2019 Non-covered Recipient Entity
ACADEMIC ALLIANCE IN DERMATOLOGY
A Placebo-Controlled, Double-Blind, Parallel-Group, 24 Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702536189
Principal investigator 1 Otsuka Pharmaceutical Development & Commercialization, Inc. $2,328.57 01/22/2019 Non-covered Recipient Entity
ACADEMIC ALLIANCE IN DERMATOLOGY
A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL TO EVALUATE THE EFFICACY, SAFETY, AND TOLERABILITY OF BREXPIPRAZOLE AS ADJUNCTIVE THERAPY IN THE MAINTENANCE TREATMENT OF ADULTS WITH MAJOR DEPRESSIVE DISORDER. No dispute reported 06/30/2026 696053269
Principal investigator 1 Janssen Research & Development, LLC $6,407.00 01/21/2019 Non-covered Recipient Entity
ACADEMIC ALLIANCE IN DERMATOLOGY
A Phase 2, Multicenter, Randomized, Placebo-Controlled, Double-Blind, Proof-of-Concept Study to Evaluate Guselkumab for the Treatment of Subjects with Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 654241457
Principal investigator 1 Janssen Research & Development, LLC $6,650.00 01/21/2019 Non-covered Recipient Entity
ACADEMIC ALLIANCE IN DERMATOLOGY
A Phase 2, Multicenter, Randomized, Placebo-Controlled, Double-Blind, Proof-of-Concept Study to Evaluate Guselkumab for the Treatment of Subjects with Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 654241459
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $79,080.53 01/14/2019 Non-covered Recipient Entity
Olympian Clinical Research - South Tampa Office
A Multi-Center, Randomized, Double-Blind, Placebo- and Active Comparator-Controlled Phase 3 Study to Evaluate the Clinical Efficacy and Safety of BMS-986165 in Subjects with Moderate to Severe Psoriasis No dispute reported 06/30/2026 639758701
Principal investigator 1 Janssen Research & Development, LLC $5,595.00 01/14/2019 Non-covered Recipient Entity
ACADEMIC ALLIANCE IN DERMATOLOGY
A Double-blind, Randomized, Active-controlled, Parallel-group Study of Paliperidone Palmitate 6-Month Formulation No dispute reported 06/30/2026 654241451
Principal investigator 1 Avanir Pharmaceuticals, Inc. $18.17 01/10/2019 Non-covered Recipient Entity
OLYMPIAN CLINICAL RESEARCH
15-AVP-786-301 No dispute reported 06/30/2026 656018053
Principal investigator 1 Avanir Pharmaceuticals, Inc. $6,525.16 01/10/2019 Non-covered Recipient Entity
OLYMPIAN CLINICAL RESEARCH
15-AVP-786-303 No dispute reported 06/30/2026 656018055
Principal investigator 1 Neurocrine Biosciences, Inc. $3,863.61 01/10/2019 Non-covered Recipient Entity
OLYMPIAN CLINICAL RESEARCH
OPEN-LABEL SAFETY AND TOLERABILITY STUDY OF NBI-98854 FOR THE TREATMENT OF PEDIATRIC SUBJECTS WITH TOURETTE SYNDROME No dispute reported 06/30/2026 686563573
Principal investigator 1 Neurocrine Biosciences, Inc. $46.00 01/03/2019 Non-covered Recipient Entity
OLYMPIAN CLINICAL RESEARCH
OPEN-LABEL SAFETY AND TOLERABILITY STUDY OF NBI-98854 FOR THE TREATMENT OF PEDIATRIC SUBJECTS WITH TOURETTE SYNDROME No dispute reported 06/30/2026 686562749
Principal investigator 1 Neurocrine Biosciences, Inc. $46.00 01/03/2019 Non-covered Recipient Entity
OLYMPIAN CLINICAL RESEARCH
SAFETY, TOLERABILITY, AND EFFICACY OF NBI-98854 FOR THE TREATMENT OF PEDIATRIC SUBJECTS WITH TOURETTE SYNDROME No dispute reported 06/30/2026 686563061
Principal investigator 1 Neurocrine Biosciences, Inc. $23.50 01/03/2019 Non-covered Recipient Entity
OLYMPIAN CLINICAL RESEARCH
OPEN-LABEL SAFETY AND TOLERABILITY STUDY OF NBI-98854 FOR THE TREATMENT OF PEDIATRIC SUBJECTS WITH TOURETTE SYNDROME No dispute reported 06/30/2026 686563095
Principal investigator 1 Neurocrine Biosciences, Inc. $2.93 01/03/2019 Non-covered Recipient Entity
OLYMPIAN CLINICAL RESEARCH
OPEN-LABEL SAFETY AND TOLERABILITY STUDY OF NBI-98854 FOR THE TREATMENT OF PEDIATRIC SUBJECTS WITH TOURETTE SYNDROME No dispute reported 06/30/2026 686563113
Principal investigator 1 Neurocrine Biosciences, Inc. $92.00 01/03/2019 Non-covered Recipient Entity
OLYMPIAN CLINICAL RESEARCH
OPEN-LABEL SAFETY AND TOLERABILITY STUDY OF NBI-98854 FOR THE TREATMENT OF PEDIATRIC SUBJECTS WITH TOURETTE SYNDROME No dispute reported 06/30/2026 686563177
Principal investigator 1 Neurocrine Biosciences, Inc. $92.00 01/03/2019 Non-covered Recipient Entity
OLYMPIAN CLINICAL RESEARCH
SAFETY, TOLERABILITY, AND EFFICACY OF NBI-98854 FOR THE TREATMENT OF PEDIATRIC SUBJECTS WITH TOURETTE SYNDROME No dispute reported 06/30/2026 686563217
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $4,921.88 01/03/2019 Non-covered Recipient Entity
ACADEMIC ALLICANCE IN DERMATOLOGY INC
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Risperidone Extended-Release Injectable Suspension (TV-46000) for Subcutaneous Use as Maintenance Treatment in Adult and Adolescent Patients With Schizophrenia No dispute reported 06/30/2026 685006305
Principal investigator 1 Biogen, Inc. $81,441.55 01/02/2019 Non-covered Recipient Entity
Academic Alliance In Dermatology
Phase 2 Study of BIIB092 in Participants With Early Alzheimer's Disease No dispute reported 06/30/2026 675311109